POA Kicks Off First International Meeting
On September 10, 2020, the POA kicked off its first ever virtual Global Molecular Oncology Summit Meeting. More than 60 clinicians representing 24 countries attended this inaugural event. Led by POA Chairman Chadi Nabhan, the meeting provided our global colleagues with an in-depth overview of the POA, its global vision, Caris International, and Caris’ products and platform.
As the POA reinforces its position as the leading cancer research enterprise in the world, it looks forward to providing the international community with the tools and resources necessary to promote the widespread adoption of precision medicine through comprehensive molecular profiling.
Dr. Sonika Dahiya to Lead POA Pathology Disease Group
The POA is proud to announce the appointment of Dr. Sonika Dahiya, Associate Professor of Pathology and Immunology from Washington University to Chair the newly formed POA Pathology Disease Group. Dr. Dahiya will be instrumental in helping to shape the curriculum and direction of this new team.
More on Dr. Dahiya can be found here.
Supporting Dr. Dahiya will be 10 Pathology Disease Group Leads. You can learn more about each of them by clicking on their names below.
Head & Neck Group
Atrium Health Earns Multiple Honors by U.S. News & World Report Including Top Hospital in Charlotte and Best in Cancer Care
Atrium Health’s Carolinas Medical Center was recognized by U.S. News & World Report as the “Best Hospital” in the Charlotte metro region for fourth consecutive year. New to the 2020-2021 rankings, Atrium Health’s Levine Cancer Institute is named among the best in the nation for cancer care and is the only cancer institute in Charlotte to be given this distinction. Read more.
Edward Chu, M.D., M.M.S., To Lead Cancer Medicine at Albert Einstein College of Medicine and Montefiore Health System
Albert Einstein College of Medicine and Montefiore Health System has announced that Edward Chu, M.D., M.M.S., has been named director of the National Cancer Institute-designated Albert Einstein Cancer Center; vice president for cancer medicine at Montefiore Medicine; professor of medicine and of molecular pharmacology; and will hold the Carol and Roger Einiger Professorship of Cancer Medicine at Einstein. In these roles, Dr. Chu will unite Einstein and Montefiore’s cancer programs into a fully integrated research and clinical enterprise. The appointment will be effective October 1, 2020. Read more.
$3.1 Million National Institutes of Health Grant Supports Exploration of Immune Response to Cancer Mutations
With the aid of a $3.1 million, five-year National Institutes of Health grant (R01CA243547), Rutgers Cancer Institute of New Jersey leaders Eileen White, PhD, Edmund Lattime, PhD, and Shridar Ganesan, MD, PhD, will collaborate on translational research exploring the immune response to cancers that feature a high number of mutations. Read more.
Sylvester Comprehensive Cancer Center receives transformational $126 million gift
A landmark gift of $126 million to the Sylvester Comprehensive Cancer Center at the University of Miami Leonard M. Miller School of Medicine will accelerate breakthrough advances in finding cures for cancer and expand innovative treatment options for cancer patients. The groundbreaking donation—the single largest in the University of Miami’s 95-year history—will further propel Sylvester’s standing as one of the nation’s preeminent cancer centers. Read more.
Penn’s Abramson Cancer Center becomes 38th member of POA
Penn Medicine’s Abramson Cancer Center is a world leader in cancer research, patient care and education. Our preeminent position is reflected in our continuous designation as a Comprehensive Cancer Center by the National Cancer Institute (NCI) since 1973, one of 51 such centers in the United States.
At the Abramson Cancer Center, we are dedicated to innovative and compassionate cancer care. Our clinical program, comprised of a dedicated staff of physicians, nurse practitioners, nurses, social workers, physical therapists, nutritionists and patient care coordinators, currently sees 305,248 outpatient visits and more than 10,230 discharges, and provides more than 81,471 chemotherapy and 66,110 radiation treatments.
Not only are we dedicated to providing state-of-the-art care, the latest forms of cancer prevention, diagnoses and treatments are available to our patients through clinical themes developed in the relentless pursuit to eliminate the pain and suffering from cancer, with more than 9,069 participants in nearly 600 clinical trials.
In addition, the Abramson Cancer Center is home to the 400+ basic, translational and clinical scientists who relentlessly work to determine the pathogenesis of cancer. Together, our faculty is committed to improving the prevention, diagnosis and treatment of cancer. Read more.
Steve Grossman, MD, PhD, named cancer physician in chief of USC Norris Comprehensive Cancer Center
LOS ANGELES — USC Norris Comprehensive Cancer Center and Keck Medicine of USC have named renowned oncologist and cancer researcher Steven Grossman, MD, PhD, as the center’s cancer physician in chief. In this inaugural position, Grossman will provide executive leadership of oncology services, partnering with academic and clinical leaders to advance new models of multidisciplinary care delivery. He will also serve as a professor of medicine at the Keck School of Medicine of USC. Read more.
CPRIT awards Mays Cancer Center more than $10.3 million
The Cancer Prevention and Research Institute of Texas awarded more than $10.3 million Aug. 19 to the Mays Cancer Center, home to UT Health San Antonio MD Anderson. The five grants include $6 million to recruit David Gius, MD, PhD, a breast cancer and radiation oncology researcher from the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. CPRIT also awarded a second recruitment grant of $2 million and three grants to individual cancer researchers. Read more.
Kennedy-Rea selected as finalist for National Cancer Award
Stephenie Kennedy-Rea, Ed.D., WVU Cancer Institute associate director for Cancer Prevention and Control, has been honored as a finalist in the second annual Cancer Community (C2) Awards Catalyst for Change category. This national award – hosted by AstraZeneca and Scientific American Custom Media –recognizes unsung heroes who have sparked impactful change in the cancer community. The Catalyst for Change category celebrates those who increase access to care for underserved populations. Read more.